Stock Events

Stock Events

Oncoinvent ASA. 

$97.09
72
+$0.00+0%Wednesday 13:30

Statistics

Day High
97.09
Day Low
97.09
52W High
97.09
52W Low
0.025
Volume
-
Avg. Volume
-
Mkt Cap
3.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Aug 27Expected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
-0.13
-0.1
-0.08
-0.06
Expected EPS
N/A
Actual EPS
N/A

Financials

-16,943.31%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
149,750.93Revenue
-25.37MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BRRGF. It's not an investment recommendation.
MPC Container Ships ASA
2
MPCC.OL
Aker BP ASA
2
AKRBP.OL
SED Energy
2
ENH.OL
Salmon Evolution ASA
2
SALME.OL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which competes with BerGenBio's cancer-focused pipeline.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. is a biotechnology company that develops and produces medicines in areas including oncology/hematology, competing directly with BerGenBio's cancer treatment developments.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. is involved in the research, development, and commercialization of drugs in areas such as oncology, directly competing with BerGenBio's therapeutic areas.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals across various areas, including cancer, making it a competitor to BerGenBio.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb Company offers biopharmaceutical products, including those for cancer treatment, competing with BerGenBio's oncology focus.
Novartis
NVS
Mkt Cap303.67B
Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, which competes with BerGenBio's product range.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products including oncology treatments, competing with BerGenBio.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG focuses on pharmaceuticals and diagnostics in oncology, among other areas, directly competing with BerGenBio's cancer therapies.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with BerGenBio.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of a range of pharmaceutical products, including those for cancer, making it a competitor to BerGenBio.

About

Oncoinvent ASA is a biopharmaceutical firm dedicated to creating novel therapies for cancer. The company concentrates its efforts on building a diverse range of AXL kinase inhibitors. Its flagship product, bemcentinib, stands out as a highly selective, orally administered small molecule designed to inhibit AXL. James Bradley Lorens and David R. Micklem established the company on December 21, 2007, and it is based in Bergen, Norway.
Show More
CEO
Oystein Soug
Employees
44
Country
Other
ISIN
NO0013711713
WKN
000A41YN5

Listings

ST
SE
BGBIOO.ST
STU
DE
7BG.STU
MU
DE
7BG.MU
LSE
GB
0RU5.LSE

0 Comments

Share your thoughts

FAQs

What is Oncoinvent ASA. stock price today?▼
The current price of BRRGF is $97.09 USD — it has increased by +0% in the past 24 hours. Watch Oncoinvent ASA. stock price performance more closely on the chart.
What is Oncoinvent ASA. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Oncoinvent ASA. stocks are traded under the ticker BRRGF.
Is Oncoinvent ASA. stock price growing?▼
BRRGF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Oncoinvent ASA. has showed a -61.16% decrease.
What is Oncoinvent ASA. market cap?▼
Today Oncoinvent ASA. has the market capitalization of 3.8B
What is Oncoinvent ASA. revenue for the last year?▼
Oncoinvent ASA. revenue for the last year amounts to 149,750.93 USD.
What is Oncoinvent ASA. net income for the last year?▼
BRRGF net income for the last year is -25.37M USD.
How many employees does Oncoinvent ASA. have?▼
As of November 5, 2026, the company has 44 employees.
In which sector is Oncoinvent ASA. located?▼
Oncoinvent ASA. operates in the Health & Wellness sector.
When did Oncoinvent ASA. complete a stock split?▼
The last stock split for Oncoinvent ASA. was on January 20, 2026 with a ratio of 1:100.
Where is Oncoinvent ASA. headquartered?▼
Oncoinvent ASA. is headquartered in Oslo, Other.